BreastScreen: balancing benefits and harms

November 4, 2011

New research has questioned the relative impact of mammographic screening in reducing deaths from breast cancer, concluding that it is not responsible for most of the recent reduction in mortality rates and may in fact cause unnecessary surgery through over-diagnosis.

The Federal Government launched Breastscreen Australia, a free program for women over 40 in 1991. In the twenty years since the program was implemented, for breast cancer have declined by 28 per cent.

In research published in and Treatment Monash University researchers concluded that the majority of that reduction cannot be attributed to earlier through mammographic screening, but is the result of improvements in treatment.

Monash University researchers, Associate Professor Robin Bell, Women’s Health Program, with Professor Robert Burton, Dr. Geetha Thiagarajah, and Dr. Christopher Stevenson of the Department of Epidemiology and Preventive Medicine analysed data from BreastScreen Australia and the Australian Institute of Health and Welfare.

Associate Professor Bell said that almost 60 per cent of the decline in mortality rates occurred before BreastScreen could have had an effect.

“Additionally, the age group showing the greatest decline in mortality over the study period had the lowest participation rates in BreastScreen,” Associate Professor Bell said. 

“When you drill down further into the data, the group with the highest screening participation rate showed no significant reduction in mortality in the period when BreastScreen should have been making an impact.

“Evidence suggests that the welcome decline in mortality rates probably results from increased use of adjuvant therapies to surgery and radiotherapy, such as chemotherapy and endocrine therapy. It’s not that we’re finding cancers earlier, it’s that we’re getting much better at treating them.”

The concern about over-diagnosis has been echoed internationally with one study finding that one in three cancers are over-diagnosed. 

“Mammographic screening is able to detect cancers before they exhibit symptoms, which can be very helpful. However, not all cancers are lethal. In some cases, they are indolent and were women not screened, they would live healthy, happy lives never knowing that they had cancer,” Associate Professor Bell said. 

“Doctors of course, cannot know which cancers will develop into a health threat, so all detected cancers are treated. This is an important area for research for the future so we get much better at determining which cancers are likely to progress.

“Women need to be better informed about the full implications of breast , and of undergoing treatment for asymptomatic cancer,” she said.

"We need to be able to clearly communicate these issues to women so they are able to make an informed choice."

Explore further: Women with breast cancer continue to smoke, drink

Related Stories

Women with breast cancer continue to smoke, drink

September 29, 2011
New research shows that Australian women are prepared to make lifestyle changes, such as altering  their diet, following diagnosis with breast cancer, however they are unwilling to give up alcohol and cigarettes - increasing ...

Study finds mammography screening reduces breast cancer mortality

June 28, 2011
Breast cancer screening with mammography results in a significant reduction in breast cancer mortality, according to long-term follow-up results of a large-scale Swedish trial. The results are published online in the journal ...

Breast screening has had little to do with falling breast cancer deaths

July 29, 2011
Breast cancer screening has not played a direct part in the reductions of breast cancer mortality in recent years, says a new study published on bmj.com today.

Recommended for you

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.